Related references
Note: Only part of the references are listed.Assessing-and Extending-California's Insulin Manufacturing Initiative
Jacob S. Sherkow et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2023)
When States Step Up: California and the Case for State-Led Insulin Manufacturing
Mariana P. Socal et al.
ANNALS OF INTERNAL MEDICINE (2022)
Associations Between Copays, Coverage Limits for Naloxone, and Prescribing in Medicaid
John C. Messinger et al.
SUBSTANCE ABUSE-RESEARCH AND TREATMENT (2022)
Trends in Out-of-Pocket Costs for Naloxone by Drug Brand and Payer in the US, 2010-2018
Evan D. Peet et al.
JAMA HEALTH FORUM (2022)
Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence A Systematic Review and Meta-analysis
Thomas Santo Jr et al.
JAMA PSYCHIATRY (2021)
Overdose Education and Naloxone Distribution Within Syringe Service Programs - United States, 2019
Barrot H. Lunbdin et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2020)
Will converting naloxone to over-the-counter status increase pharmacy sales?
Sean M. Murphy et al.
HEALTH SERVICES RESEARCH (2019)
Naloxone urban legends and the opioid crisis: what is the role of public health?
Alexis Crabtree et al.
BMC PUBLIC HEALTH (2019)
Fentanyl test strips as an opioid overdose prevention strategy: Findings from a syringe services program in the Southeastern United States
Nicholas C. Peiper et al.
INTERNATIONAL JOURNAL OF DRUG POLICY (2019)
The Rising Price of Naloxone - Risks to Efforts to Stem Overdose Deaths
Ravi Gupta et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Increases in Drug and Opioid-Involved Overdose Deaths - United States, 2010-2015
Rose A. Rudd et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2016)